当前位置:首页 - 行情中心 - 硕世生物(688399) - 财务分析 - 利润表

硕世生物

(688399)

  

流通市值:62.97亿  总市值:62.97亿
流通股本:8387.17万   总股本:8387.17万

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入257,507,844.76175,580,501.6591,608,367.51349,608,940.74
  营业收入257,507,844.76175,580,501.6591,608,367.51349,608,940.74
二、营业总成本306,781,790.65206,509,908.26102,757,882.33420,490,233
  营业成本94,729,081.3965,946,207.7938,539,428.43131,954,198.13
  税金及附加5,395,900.143,599,615.061,748,315.496,723,295.14
  销售费用94,147,522.5564,247,915.8530,480,848.9131,328,069.26
  管理费用49,138,901.7131,679,713.2915,114,741.5582,571,362.28
  研发费用61,550,504.7940,640,611.8919,092,486100,886,641.37
  财务费用1,819,880.07395,844.38-2,217,938.04-32,973,333.18
  其中:利息费用6,318,679.765,010,137.562,099,332.247,745,925.46
  其中:利息收入4,986,114.854,861,108.764,264,203.9339,779,406.31
三、其他经营收益
  加:公允价值变动收益31,779,316.4824,119,828.210,042,281.762,182,658.64
  加:投资收益5,460,640.693,678,436.11,460,090.43-1,350,660.89
  资产处置收益183,362.84329,458.59254,606.272,223,291.77
  资产减值损失(新)-11,808,595.38-8,875,990.18-404,167.43-25,015,532.3
  信用减值损失(新)12,353,476.014,911,481.423,587,137.3536,107,911.71
  其他收益18,260,142.6613,686,217.4110,199,412.1465,548,152.45
四、营业利润6,954,397.416,920,024.9313,989,845.78,814,529.12
  加:营业外收入242,549.54132,507.650.03788,607.93
  减:营业外支出71,478.2239,590.5127,288.415,415,932.9
五、利润总额7,125,468.737,012,942.0713,962,557.324,187,204.15
  减:所得税费用3,973,806.593,020,327.461,143,125.426,188,899.96
六、净利润3,151,662.143,992,614.6112,819,431.9-2,001,695.81
(一)按经营持续性分类
  持续经营净利润3,151,662.143,992,614.6112,819,431.9-2,001,695.81
(二)按所有权归属分类
  归属于母公司股东的净利润3,151,662.143,992,614.6112,819,431.9-2,001,695.81
  扣除非经常损益后的净利润-41,392,502.88-28,047,868.81-5,580,541.06-71,837,106.84
七、每股收益
  (一)基本每股收益0.040.050.23-0.03
  (二)稀释每股收益0.040.050.23-0.03
八、其他综合收益-1,054,497.65266,808.82--4,982,289.21
  归属于母公司股东的其他综合收益-1,054,497.65266,808.82--4,982,289.21
九、综合收益总额2,097,164.494,259,423.4312,819,431.9-6,983,985.02
  归属于母公司股东的综合收益总额2,097,164.494,259,423.4312,819,431.9-6,983,985.02
公告日期2025-10-252025-08-092025-04-302025-04-19
审计意见(境内)标准无保留意见
TOP↑